Pharma MarXMAD:PHM +1.11%86 OCF Margin % is 20.01% as of Mar. 2026, which is 1476% above its 10-year median of 1.27. GuruFocus rates XMAD:PHM with a GF Score™ of 86/100 and a GF Value™ of €83.14 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 960 Biotechnology companies, Pharma Mar ranks better than 87.4% on this metric.
The historical rank and industry rank for Pharma Mar's OCF Margin % or its related term are showing as below:
XMAD:PHM'
s OCF Margin % Range Over the Past 10 Years
Min: -28.21 Med: 1.27 Max: 103.33
Current: 25.83
During the past 13 years, the highest OCF Margin % of Pharma Mar was 103.33%. The lowest was -28.21%. And the median was 1.27%.
XMAD:PHM's OCF Margin % is ranked better than 87.4% of 960
companies
in the Biotechnology industry
Industry Median: -68.59
vs XMAD:PHM: 25.83
Pharma Mar OCF Margin % Related Terms
Pharma Mar OCF Margin % Historical Data
* Premium members only.
The historical data trend for Pharma Mar's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:PHM vs VRTX, REGN, ALNY: OCF Margin % Comparison
For the Biotechnology subindustry, Pharma Mar's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Mar OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharma Mar's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Pharma Mar's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma Mar (XMAD:PHM) has a OCF Margin % of 20.01% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Pharma Mar and its competitors. This is 1476% above median its historical median of 1.27. According to the industry distribution chart, Pharma Mar ranks #121 out of 960 companies in the Biotechnology industry, placing it in the top 12.6%.
Is Pharma Mar's OCF Margin % too high?
Pharma Mar's current OCF Margin % of 20.01% is 1476% above median its 10-year median of 1.27. Based on the distribution chart, Pharma Mar ranks #121 out of 960 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pharma Mar has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma Mar's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharma Mar ranks #121 out of 960 companies for OCF Margin %. This places Pharma Mar in the top 13% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Pharma Mar and its competitors. Pharma Mar's current OCF Margin % is 20.01%, which is 1476% above median its own 10-year median of 1.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Mar stock overvalued right now?
Based on GuruFocus' analysis, Pharma Mar (XMAD:PHM) is currently considered Modestly Undervalued. The stock's GF Value™ is €83.14, compared to a current price of €72.90 — trading 12.3% below its estimated fair value. The current OCF Margin % is 20.01%, which is 1476% above median its 10-year median of 1.27. Pharma Mar's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Pharma Mar (XMAD:PHM), the current OCF Margin % is 20.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma Mar (XMAD:PHM) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma Mar stock appears to be undervalued.
The current stock price of €72.90 is trading 12.3% below its estimated GF Value™ of €83.14.
GuruFocus considers Pharma Mar to be Modestly Undervalued.
Key valuation signals for XMAD:PHM:
OCF Margin %: 20.01% (1476% above median its 10-year median of 1.27)
GF Value™: €83.14 vs. price of €72.90 (12.3% below fair value)
No single metric tells the full story. See the XMAD:PHM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
86GF Score
Get the complete analysis for XMAD:PHM
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:PHM has been successfully added to your 
